Brad Barnett
Chief Tech/Sci/R&D Officer bij COGENT BIOSCIENCES, INC.
Profiel
Brad Barnett is currently the Chief Technology Officer at Cogent Biosciences, Inc. Prior to his current position, he worked at Array BioPharma, Inc. from 2000 to 2019, where he held the position of Vice President-Supply Chain & Manufacturing from 2015 to 2019.
Mr. Barnett received an undergraduate degree from Colorado State University and an MBA from The University of Colorado.
Actieve functies van Brad Barnett
| Bedrijven | Functie | Begin |
|---|---|---|
| COGENT BIOSCIENCES, INC. | Chief Tech/Sci/R&D Officer | - |
Eerdere bekende functies van Brad Barnett
| Bedrijven | Functie | Einde |
|---|---|---|
| ARRAY TECHNOLOGIES, INC. | Corporate Officer/Principal | 01-08-2019 |
Opleiding van Brad Barnett
| Colorado State University | Undergraduate Degree |
| The University of Colorado | Masters Business Admin |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| COGENT BIOSCIENCES, INC. | Health Technology |
| Bedrijven in privébezit | 1 |
|---|---|
Array BioPharma, Inc.
 Array BioPharma, Inc. Pharmaceuticals: MajorHealth Technology Array BioPharma, Inc. is a biopharmaceutical company. Its focus is on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer and other high-burden diseases. The company's products are BRAFTOVI and MEKTOVI. Its portfolio includes Binimetinib, Selumetinib, Encorafenib, Filanesib, Ipatasertib, Varltinib, Danoprevir, ARRY-797, Larotrectinib, Tucatinib, ARRY-382, Motolimod, Prexasertib, GDC-0575, LOXO-292, LOXO-195, and AK-1830. The company was founded by Kevin Koch, Anthony D. Piscopio, K. C. Nicolaou, and David L. Snitman in 1998 and is headquartered in Boulder, CO. | Health Technology |
